**AOD-9604 clinical data:** - One Phase 2b clinical trial was conducted in approximately 300 obese adults in Australia - Results showed **no statistically significant difference** in weight loss between AOD-9604 and placebo groups - The trial was considered a failure, and Metabolic Pharmaceuticals did not advance AOD-9604 to Phase 3 - Total clinical weight loss data in humans: fewer than 500 participants across all studies - Typical AOD-9604 results reported anecdotally: 1-3 kg over several months **Semaglutide clinical data:** - The STEP clinical trial program included over **4,500 participants** across multiple Phase 3 trials - STEP 1 demonstrated **14.9% mean body weight loss** (vs 2.4% placebo) over 68 weeks - STEP 5 confirmed weight loss maintenance of approximately **15.2%** over two full years - STEP 4 showed that discontinuing semaglutide leads to weight regain, confirming its active role in fat loss - The SELECT trial (17,604 participants) demonstrated a **20% reduction in major cardiovascular events** - Total clinical participants: over 20,000 across all weight loss and cardiovascular trials | Metric | AOD-9604 | Semaglutide | |--------|----------|-------------| | Phase 3 weight loss trial | Failed / not completed | Multiple successful trials | | Mean weight loss (%) | Not statistically significant vs placebo | 14.9-16.9% body weight | | Total clinical participants | ~500 | 20,000+ | | FDA approval for weight loss | No | Yes (Wegovy) | | Cardiovascular outcomes data | None | Yes (SELECT trial 20% MACE reduction) | | Long-term data (2+ years) | None | Yes (STEP 5) | | Published in top journals | Limited | NEJM, JAMA, Lancet, Nature Medicine | ### Safety and Side Effects **AOD-9604 side effects:** - Generally well-tolerated in limited studies - Injection site reactions - Headache (infrequent) - No significant GI side effects - **Critical caveat:** The absence of side effects partly reflects the lack of robust biological activity in humans **Semaglutide side effects:** - Nausea (most common, typically transient resolves with dose titration) - Vomiting, diarrhea, constipation - Injection site reactions - Rare reports of pancreatitis - Well-characterized safety profile from extensive clinical trials - Most GI side effects can be managed with proper [dose titration](/guides/semaglutide-dosing-schedule-week-by-week-guide) For guidance on proper **peptide injection** technique to minimize discomfort, see our [GLP-1 injection guide](/guides/how-to-inject-glp1-medications-guide)
Injectable semaglutide can be taken at any time of day, with or without meals
When administered under medical supervision, peptide treatments can help: Encourage fat utilization for energy Improve metabolic efficiency Support lean muscle preservation Enhance recovery and vitality These benefits make peptides a growing component of comprehensive wellness programs offered at a medical weight loss clinic focused on long-term health outcomes
Other Ingredients:Water, Aloe (Aloe vera barbadensis) (leaf) juice, propanediol (all natural, petroleum-free), MSM (methylsulfonylmethane), cetyl alcohol, urea, octyl palmitate, triethanolamine, stearic acid (vegetable source), panthenol, PEG-8 stearate, glycerin, polysorbate 65, coconut (Cocos nuciferas), gardenia (Gardenia tahitensis) (flower) extract, sodium hyaluronate, natural vitamin E (d-tocopheryl), TEA-carbomer, orange (Citrus aurantium dulcis)(peel) oil, diazolidinyl urea, iodopropynyl butylcarbamate, grapefruit (Citrus grandis) (peel) oil,grapefruit (Citrusgrandis) (peel) extract
But the right medication depends on safety, side effects, coverage, dose tolerance, and the patients long-term plan
Instead, it helps restore your skin's natural glow by reducing dullness, tanning, and pigmentation through regular use
